NovoCure (BSP:N2VC34) Total Equity: R$1,730 Mil (As of Mar. 2026)


BSP:N2VC34 NovoCure Ltd BSP:N2VC34
46 GF Score
Price R$7.08
GF Value R$8.98
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is NovoCure Total Equity?

NovoCure BSP:N2VC34 46 Total Equity is R$1,730 Mil as of Mar. 2026. GuruFocus rates BSP:N2VC34 with a GF Score™ of 46/100 and a GF Value™ of R$8.98 (Modestly Undervalued). The stock has 5 warning signs investors should review.

NovoCure's total equity for the quarter that ended in Mar. 2026 was R$1,730 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

NovoCure Total Equity Historical Data

* Premium members only.

The historical data trend for NovoCure's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NovoCure Total Equity Chart

NovoCure Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,321.30 2,314.11 1,776.16 2,197.45 1,857.48

NovoCure Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,084.19 1,937.93 1,830.57 1,857.48 1,729.52
BSP:N2VC34
46GF Score
NovoCure Ltd BSP:N2VC34
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NovoCure Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

NovoCure's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=4388.161-2530.681
=1,857

NovoCure's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=4120.538-2391.02
=1,730

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of R$1,730 Mil mean?
NovoCure (BSP:N2VC34) has a Total Equity of R$1,730 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for NovoCure and its competitors.
Is NovoCure's Total Equity too high?
NovoCure's current Total Equity is R$1,730 Mil. Overall, NovoCure has a GF Score™ of 46/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NovoCure's Total Equity compare to NEOG and ESTA?
NovoCure's Total Equity of R$1,730 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Devices & Instruments company?
A good Total Equity depends on the Medical Devices & Instruments industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for NovoCure and its competitors. NovoCure's current Total Equity is R$1,730 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NovoCure stock overvalued right now?
Based on GuruFocus' analysis, NovoCure (BSP:N2VC34) is currently considered Modestly Undervalued. The stock's GF Value™ is R$8.98, compared to a current price of R$7.08 — trading 21.2% below its estimated fair value. The current Total Equity is R$1,730 Mil. NovoCure's overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For NovoCure (BSP:N2VC34), the current Total Equity is R$1,730 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NovoCure (BSP:N2VC34) Overvalued in 2026?

Based on GuruFocus' analysis, NovoCure stock appears to be undervalued. The current stock price of R$7.08 is trading 21.2% below its estimated GF Value™ of R$8.98. GuruFocus considers NovoCure to be Modestly Undervalued.

Key valuation signals for BSP:N2VC34:

  • Total Equity: R$1,730 Mil
  • GF Value™: R$8.98 vs. price of R$7.08 (21.2% below fair value)
  • GF Score™: 46/100 with 5 warning signs

No single metric tells the full story. See the BSP:N2VC34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NovoCure Business Description

Address Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
46GF Score

Get the complete analysis for BSP:N2VC34

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$7.08
Price
R$8.98
GF Value